Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics to Present at Jefferies 2017

RNS Number: 2495W Allergy Therapeutics PLC 13 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference 13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces th...

Director/PDMR Shareholding

RNS Number: 8138V Allergy Therapeutics PLC 07 November 2017 The announcement released by Allergy Therapeutics plcentitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as 0.0001 per share. The correct exercise price is 0.001. All other figures remain unchanged. The correct figure is included in the reissued ann...

Director/PDMR Shareholding

RNS Number: 8006V Allergy Therapeutics PLC 07 November 2017 07 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Grant of Options under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance c...

Publication of Annual Report and notice of AGM

RNS Number: 1267U Allergy Therapeutics PLC 19 October 2017 19 October 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING Allergy Therapeutics Plc has today published the following documents: Annual Report for the year ended 30 June 201...

All News

DateHeadlineSource
30-12-16Grant of AwardsRNS
25-11-16Allergy Therapeutics resolutions passed at AGMStockMarketWire
24-11-16Result of AGMRNS
02-11-16Allergy Therapeutics granted EU patent StockMarketWire
02-11-16EU Patent Office grants patent for MCTRNS
27-10-16Issue of equity in respect of exercise of optionsRNS
24-10-16Annual Report and AccountsRNS
14-10-16Share of the week: Tipped to double againInteractive Investor
10-10-16New data from novel adjuvant systemRNS
03-10-16Issue of equity in respect of exercise of optionsRNS
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
26-09-16Director/PDMR ShareholdingRNS
26-09-16Hardman Research: Performance drives market shareRNS
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics Preliminary ResultsRNS
21-09-16Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
21-09-16Allergy Therapeutics options exercised StockMarketWire
20-09-16Issue of equity in respect of exercise of optionsRNS
05-09-16Allergy Therapeutics schedules FY results StockMarketWire
05-09-16Notice of Preliminary ResultsRNS
31-08-16Allergy Therapeutics Plc to present at the Shares Investor Evening in London on 27th September 2016StockMarketWire
13-07-16Trading UpdateRNS
08-07-16Results of mite immunotherapy Acarovac PlusTRNS
27-06-16Findings from mEEC dose range finding study G204RNS
13-06-16Allergy Therapeutics' satellite symposium at EAACIStockMarketWire
13-06-16Allergy hosts Satellite Symposium at EAACIRNS
10-06-16Appointment of Finance DirectorRNS
18-05-16Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breedMotley Fool
09-05-16Allergy Therapeutics positive data from PQBirch204 studyStockMarketWire
09-05-16Positive Phase II DataRNS
21-04-16This list of shares keeps outperformingInteractive Investor
23-03-16Allergy Therapeutics options exercised StockMarketWire
23-03-16Issue of equity in respect of options exerciseRNS
17-03-16Allergy Therapeutics FD resigns StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account